Janus-faced? Effects and side-effects of interferon therapy in ophthalmology;Ein Januskopf? Wirkungen und Nebenwirkungen der Interferontherapie in der Augenheilkunde

Ophthalmologe

Volumn 108, Issue 3, 2011, Pages 204-212

  Stubiger N ^a   Winterhalter, S ^a   Pleyer, U ^a   Doycheva, D ^b   Zierhut, M ^b   Deuter, C ^b  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^b UNIVERSITY HOSPITAL TÜBINGEN   (Germany)

Author keywords

Beh et's disease; Interferon; Macular edema; Side effects; Uveitis

Indexed keywords

ALPHA INTERFERON; BETA INTERFERON;

ANIMAL; ANTIBODY PRODUCTION; ARTICLE; BEHCET DISEASE; CYTOTOXICITY; DELAYED HYPERSENSITIVITY; DOSE RESPONSE; DRUG EFFECT; EYE DISEASE; FOLLOW UP; HUMAN; IMMUNOLOGY; LYMPHOCYTE ACTIVATION; MULTIPLE SCLEROSIS; RETINA MACULA EDEMA; RETINA VASCULITIS; UVEITIS;

ANIMALS; ANTIBODY FORMATION; BEHCET SYNDROME; CYTOTOXICITY, IMMUNOLOGIC; DOSE-RESPONSE RELATIONSHIP, DRUG; EYE DISEASES; FOLLOW-UP STUDIES; HUMANS; HYPERSENSITIVITY, DELAYED; INTERFERON-ALPHA; INTERFERON-BETA; LYMPHOCYTE ACTIVATION; MACULAR EDEMA; MULTIPLE SCLEROSIS; RETINAL VASCULITIS; UVEITIS;

EID: 79952991971     PISSN: 0941293X     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00347-010-2261-1     Document Type: Article

References (52)

1. Archambeau PL, Hollenhorst RW, Rucker CW (1965) Posterior uveitis as a manifestation of multiple sclerosis. Mayo Clin Proc 40: 544-551.
2. Becker MD, Heiligenhaus A, Hudde T et al (2005) Interferon as a treatment for uveitis associated with multiple sclerosis. Br J Ophthalmol 89: 1254-1257.
3. Belardelli F, Gresser I (1996) The neglected role of type I interferon in the T-cell response: implications for its clinical use. Immunol Today 17: 369-372.
4. BenEzra D, Cohen E (1986) Treatment and visual prognosis in Behçet's disease. Br J Ophthalmol 70: 589-592.
5. Biousse V et al (1999) Multiple sclerosis associated with uveitis in two large clinic-based series. Neurology 52(1): 179-181.
6. Bodaghi B, Gendron G, Wechsler B et al (2007) Efficacy of interferon alpha in the treatment of refractory and sight threatening uveitis: a retrosprective monocentric study of 45 patients. Br J Ophthalmol 91: 335-339.
7. Brasnu E, Wechsler B, Bron A et al (2005) Efficacy of interferon-alpha for the treatment of Kaposi's sarcoma herpesvirus-associated uveitis. Am J Ophthalmol 140: 746-748.
8. Conlon KC, Urba WJ, Smith JW et al (1990) Exacerbation of symptoms of autoimmune disease in patients receiving interferon-alpha therapy. Cancer 65: 2237-2242.
9. Deuter CME, Kötter I, Günaydin I et al (2006) Interferon alfa-2a: a new treatment option for long lasting refractory cystoid macular edema in uveitis? A pilot study. Retina 26: 786-791.
10. Deuter CM, Kötter I, Günaydin I et al (2009) Efficacy and tolerability of interferon alpha treatment in patients with chronic cystoid macular oedema due to non-infectious uveitis. Br J Ophthalmol 93: 906-913.
11. Deuter CM, Zierhut M, Möhle A et al (2010) Long-term remission after cessation of interferon-α treatment in patients with severe uveitis due to Behçet's disease. Arthritis Rheum 62(9): 2796-2805.
12. Doycheva D, Deuter CME, Stübiger N et al (2009) Interferon-alpha associated presumed ocular sarcoidosis. Graefes Arch Clin Exp Ophthalmol 247: 675-680.
13. Gillies MC, Su T (1995) Interferon alpha2b enhances barrier function of bovine retinal microvascular endothelium in vitro. Microvasc Res 49: 277-288.
14. Green AR, Vassilou GS, Curtin N et al (2004) Management of the myeloproliferative disorders: distinguishing data from dogma. Hematol J 5: 126-132.
15. Gueudry J, Wechsler B, Terrada C et al (2008) Long-term efficacy and safety of low-dose interferon alpha2a therapy in severe uveitis associated with Behcet's disease. Am J Ophthalmol 146: 837-844.
16. Guillaume-Czitrom E, Berger C, Pajot C et al (2007) Efficacy and safety of interferon-alpha in the treatment of corticodependent uveitis of paediatric Behcet's disease. Rheumatology 46: 1570-1573.
17. Hamuryudan V, Ozyazgan Y, Fresko Y et al (2002) Interferon alfa combined with azathioprine for the uveitis of Behcet's disease: an open study. Isr Med Assoc J 4: 928-930.
18. Hatemi G, Bang D, Bodaghi B et al (2008) EULAR recommendations for the management of Behçet's disease: report of a task force of the European Standing Committee for InternationalClinical Studies Including Therapeutics (ESCISIT). Ann Rheum Dis 67: 1656-1662.
19. Hoffmann A, Kim E, Krueger GR et al (1994) Bone marrow hypoplasia and fibrosis following interferon treatment. In Viva 8: 605-612.
20. Hurst EA, Mauro T (2005) Sarcoidosis associated with pegylated interferon alfa and ribavirin treatment for chronic hepatitis C: a case report and review of the literature. Arch Dermatol 141: 865-868.
21. Imrie FR, Dick AD (2007) Biologicals in the treatment of uveitis. Curr Opin Ophthalmol 18: 481-486.
22. InternationalStudy Group for Behçet's disease (1990) Criteria for diagnosis of Behçet's disease. Lancet 335: 1078-1080.
23. Isaacs A, Lindemann J (1957) Viral interference. I. The interferon. Proc R Soc Lond B Biol Sci 147(927): 258-267.
24. Kötter I, Zierhut M, Eckstein AK et al (2003) Human recombinant interferon alfa-2a for the treatment of Behcet's disease with sight threatening posterior or panuveitis. Br J Ophthalmol 87: 423-431.
25. Kötter I, Günaydin I, Zierhut M et al (2004) The use of interferon alpha in Behcet's disease: review of the literature. Semin Arthritis Rheum 33: 320-335.
26. Krause L, Altenburg A, Pleyer U et al (2008) Longterm visual prognosis of patients with ocular Adamantiades-Behçet's disease treated with interferon-alfa-2a. J Rheumatol 35(5): 896-903.
27. Mackensen F, Regina M, Becker MD (2009) Interferons an their potential in the treatment of ocular inflammation. Clin Experiment Ophthalmol 3: 559-566.
28. Mackensen F et al (2010) Long-term results of a monocentric controlled clinical trial comparing interferon beta with methotrexate in the treatment of uveitis macular edema. ARVO Abstract 2916.
29. Mishima S, Masuda K, Izawa Y, Mochizuki M (1979) Behçet's disease in Japan: Ophthalmologic aspects. Tr AM Ophth Soc LXXVII: 225-279.
30. Montvale NJ (2000) Physicans desk reference. Medical Economics Company, Montvale, NJ, S 2654-2658, 2808-2817.
31. Okada AA, Keino H, Fukai T (1998) Effect of type I interferon on experimental autoimmune uveoretinitis in rats. Ocul Immunol Inflamm 6: 209-210.
32. Okada AA (2005) Immunomodulatory therapy for ocular inflammatory disease: a basic manual and review of the literature. Ocul Immunol Inflamm 13: 335-351.
33. Okada H, Pollack IF (2004) Cytokine gene therapy for malignant glioma. Expert Opin Biol Ther 4: 1609-1620.
34. Plskova J, Greiner K, Muckersie E et al (2006) Interferon-alpha: a key factor in autoimmune disease? Invest Ophthalmol Vis Sci 47(9): 3946-3950.
35. Plskova J, Greiner K, Forrester JV (2007) Interferon-α as an effective treatment for noninfectious posterior uveitis and panuveitis. Am J Ophthalmol 144(1): 55-61.
36. Purvin VA (1995) Anterior ischemic optic neuropathy secondary to interferon alfa. Arch Ophthalmol 113(8): 1041-1044.
37. Saadeh S, Davis GL (2004) The evolving treatment of chronic hepatitis C: where we stand a decade out. Cleve Clin J Med 71: 3-7.
38. Sobaci G, Bayraktar Z, Bayer A (2005) Interferon alpha-2a treatment for serpinginous choroiditis. Ocul Immunol Inflamm 13: 59-66.
39. Sobaci G, Erdem U, Durukan AH et al (2010) Safety and effectiveness of interferon alpha-2a in treatment of patients with Behçet's uveitis refractory to conventional treatments. Ophthalmology 117: 1430-1435.
40. Saito H, Ebinuma G, Satoh H et al (2000) Immunological and virological predictors of outcome during interferon-alpha therapy of chronic hepatitis C. J Viral Hepat 7: 64-74.
41. Stoutenburg JP, Schrope B, Kaufmann HL (2004) Adjuvant therapy for malignant melanoma. Expert Rev Anticancer Ther 8: 823-835.
42. Stübiger N, Kötter I, Zierhut M (2000) Complete regression of retinal neovascularisation after therapy with interferon alfa in Behcet's disease. Br J Ophthalmol 84: 1437-1438.
43. Stübiger N, Kötter I, Deuter CM et al (2001) Behcet's disease: uveitis-therapy with interferon alpha2a - prospective clinical study in 33 patients. Klin Monatsbl Augenheilkd 528: 768-773.
44. Stübiger N, Crane I, Kötter I et al (2003) Interferon alpha2a in IRBP-derived peptide induced EAU - part I. Adv Exp Med Biol 528: 537-540.
45. Suzuki J, Sakai J, Okada AA et al (2002) Oral administration of interferon-beta suppresses experimental autoimmune uveoretinitis. Graefes Arch Clin Exp Ophthalmol 240: 314-321.
46. Treusch M, Vonthein R, Baur M et al (2004) Influence of human recombinant interferon-alpah2a (rhIFNalpha2a) on altered lymphocyte subpopulations and monocytes in Behçet's disease. Rheumatology 43(10): 1275-1282.
47. Tsambaos D, Eichelberg D, Goos M (1986) Behçet's syndrome: treatment with recombinant leukocyte alpha-interferon. Arch Dermatol Res 278: 335-336.
48. Tugal-Tutgun I, Guney-Tefekli E, Urgancioglu M (2006) Results of interferon-alfa therapy in patients with Behçet's uveitis. Graefes Arch Clin Exp Ophthalmol 244: 1692-1695.
49. Usui Y, Takeuchi M, Hattori T et al (2009) Suppression of experimental autoimmune uveoretinitis by regulatory dentritic cells in mice. Arch Ophthalmol 127: 514-519.
50. Vandenbark AA, Huan J, Agotsch M et al (2009) Interferon-beta-1a treatment increases CD56(bright) natural killer cells and CD4+CD25+ Foxp3 expression in subjects with multiple sclerosis. J Neuroimmunol 215(1-2): 125-128.
51. Wang W, Edington HD, Rao UN et al (2008) Effects of high dose IFN alpha2b on regional lymph node metastases of human melanoma: modulation of STAT5, FOXP3 and IL-17. Clin Cancer Res 14(24): 8314-8320.
52. Yang DS, Galatowicz G, Calder VL et al (2009) Upregulation of Foxp3 expression by recombinant interferon-alpha therapy in Behcet's disease. ARVO Poster No. 1535.